## **AMENDMENTS TO THE CLAIMS**

Docket No.: 0020-5301PUS1

Claims 1-19 (Cancelled)

- 20. (New) A liquid preparation consisting essentially of:
- (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the formula [I]:

$$X^{1}$$
-Alk-O  $\stackrel{\text{II}}{\longrightarrow}$   $\stackrel{\text{N}}{\longrightarrow}$   $\stackrel{\text{O}}{\longrightarrow}$   $\stackrel$ 

wherein R<sup>1</sup> is a substituted or unsubstituted lower alkyl group, X<sup>1</sup> is a group of the formula: -NHR<sup>2</sup> (wherein R<sup>2</sup> is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,

- (b) a buffer and
- (c) water,

which is adjusted to pH 5 - 8 with said buffer.

- 21. (New) A liquid preparation consisting essentially of:
- (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the formula [I]:

2

$$X^{1}$$
-Alk-O  $\stackrel{\text{II}}{\text{II}}$   $\stackrel{\text{O}}{\text{N}}$   $\stackrel{\text{O}}{\text{O}}$   $\stackrel{\text{O}}{\text{O}}$   $\stackrel{\text{I}}{\text{I}}$   $\stackrel{\text{O}}{\text{O}}$ 

RCS/njp

wherein R<sup>1</sup> is a substituted or unsubstituted lower alkyl group, X<sup>1</sup> is a group of the formula: -NHR<sup>2</sup> (wherein R<sup>2</sup> is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,

- (b) one or more stabilizers selected from an alkali metal carbonate and an alkali metal hydrogencarbonate,
- (c) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and
- (d) water, which is adjusted to pH 5 8 with said buffer.
  - 22. (New) A liquid preparation consisting essentially of:
- (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the formula [I]:

$$X^{1}$$
-Alk-O  $I$   $N$   $H_{5}C_{2}^{I}$   $O$   $O$   $I$   $I$ 

wherein R<sup>1</sup> is a substituted or unsubstituted lower alkyl group, X<sup>1</sup> is a group of the formula: -NHR<sup>2</sup> (wherein R<sup>2</sup> is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,

(b) one or more salts selected from the group consisting of an alkali metal chloride, an alkali earth metal chloride and an alkali metal sulphate,

3

RCS/njp

Docket No.: 0020-5301PUS1

(c) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and

(d) water, which is adjusted to pH 5 - 8 with said buffer.

- 23. (New) A liquid preparation consisting essentially of:
- (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the formula [I]:

wherein R<sup>1</sup> is a substituted or unsubstituted lower alkyl group, X<sup>1</sup> is a group of the formula: -NHR<sup>2</sup> (wherein R<sup>2</sup> is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,

- (b) one or more salts selected from the group consisting of an alkali metal chloride, an alkali earth metal chloride and an alkali metal sulphate,
- (c) one or more stabilizers selected from an alkali metal carbonate and an alkali metal hydrogencarbonate,
- (d) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and
- (e) water, which is adjusted to pH 5 8 with said buffer.

4 RCS/njp

Docket No.: 0020-5301PUS1

24. (New) The liquid preparation according to claim 20, 21, 22 or 23, wherein the camptothecin derivative is one prepared by binding a compound of the following formula:

and a carboxymethylated dextran via glycyl-glycyl-glycine, and the buffer is one comprising citric acid and sodium dihydrogenphosphate.

- 25. (New) The liquid preparation according to claim 24 wherein the ionic strength of the buffer is 0.2 or less than 0.2.
- 26. (New) The liquid preparation according to claim 25 wherein the pH is adjusted to 5 to 7.5.
- 27. (New) The liquid preparation according to claim 25 wherein the pH is adjusted to 5 to 7.
- 28. (New) The liquid preparation according to claim 25 wherein the pH is adjusted to 6 to 7.
- 29. (New) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in claim 24.
- 30. (New) The liquid preparation according to claim 23, wherein the salt is sodium chloride.

5 RCS/njp

Docket No.: 0020-5301PUS1

Application No. 10/509,912 Docket No.: 0020-5301PUS1 Amendment dated December 5, 2008

31. (New) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in claim 20.

- 32. (New) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in claim 21.
- 33. (New) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in claim 22.
- 34. (New) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in claim 23.

6 RCS/njp